Rodent Surgery Services MarketSize, Share & Industry Analysis, 2026-2034By TypeBy ApplicationBy Animal TypeBy IndicationBy Service Model

Rodent surgery services cover the surgical creation and preparation of mouse and rat models used in preclinical research, from disease-induction procedures such as tumor implantation and cardiovascular or metabolic surgery to the pre-implantation of telemetry devices, osmotic pumps and vascular or intrathecal cannulas ahead of a study. These procedures are carried out either inside a sponsor's own vivarium or by a specialist contract provider, and are delivered as a live, surgically prepared animal ready for a research protocol rather than as a device or reagent. Buyers are pharmaceutical and biopharmaceutical companies, contract research organizations, and academic or government research institutes commissioning models to support drug discovery, safety and efficacy studies.

Growth of 9.4% a year carries the global rodent surgery services market from USD 420 million in 2025 to USD 942 million in 2034. The full series behind that rate covers USD 265 million in 2020, USD 378 million in 2024, USD 459 million in 2026 and USD 657 million in 2030, with 2025 as the base year.

The type mix shifts over the period. Pathological Model is the largest line in 2025 at USD 264.6 million, a 63% share, moving to USD 546.36 million and 58% by 2034. Pre-Implanted Model grows fastest at 10.93%, taking its share from 37% to 42%, while Pathological Model grows slowest at 8.41%. Share moves toward Pre-Implanted Model and away from Pathological Model, though no line shrinks in revenue terms.

By application, Pharmaceutical/Biopharmaceutical Companies accounts for 44% of 2025 revenue at USD 184.8 million, reaching USD 395.64 million and 42% by 2034. Contract Research Organizations grows faster at 10.61% against 8.83%, moving from 38% of revenue to 42% by 2034. This axis divides the same revenue as the type split rather than adding to it, so the two are read together rather than summed.

USD 176.4 million of 2025 revenue is generated in North America, 42% of the global total and the largest regional share; it reaches USD 348.54 million by 2034. Europe is next at 27% and USD 113.4 million, and Middle East and Africa last at 4%. Share shifts toward Asia Pacific, Latin America and Middle East and Africa over the forecast period, which is what makes the regional split worth reading rather than assuming.

Coverage extends to five regions, two type lines and five segmentation axes over the full fifteen years. The 2025 total itself is a triangulation of published figures and category proxies rather than a directly sourced total, and the splits below are estimated on that same basis, a bound on their precision worth carrying into any use of them.

• The global rodent surgery services market moves from USD 265 million in 2020 to USD 420 million in 2025 and USD 942 million by 2034, the forecast period compounding at 9.4% a year.
• 63% of 2025 revenue sits in Pathological Model (USD 264.6 million) and it remains the largest type line in 2034 at USD 546.36 million and 58%.
• Pre-Implanted Model is the fastest-growing line at 10.93%, lifting its share from 37% in 2025 to 42% in 2034 and its revenue from USD 155.4 million to USD 395.64 million.
• The bull case puts 2034 revenue at USD 1036.2 million and the bear case at USD 847.8 million, either side of the USD 942 million base case, each with its own stated assumption in the full report.
• 42% of 2025 revenue is generated in North America, worth USD 176.4 million and rising to USD 348.54 million by 2034; Middle East and Africa is smallest at 4%.
• The United States accounts for 85% of North America in the base year, worth USD 149.94 million in 2025 and reaching USD 292.7736 million by 2034, the worked country example carried through that region's chapters.
• Every line on all five segmentation axes and in each of the five regions carries its own revenue, share and growth rate for all fifteen years, 2020 through 2034, on a 2025 base.

Three things move over 2026-2034, and they are worth separating: the type mix, the regional balance, and the 9.4% compounding underneath both.

The direction of the market is not in question in any of the three. Each line and each region grows in revenue terms; the question is which takes the larger part of the growth.

Pre-Implanted Model grows faster than Pathological Model. Between 2026 and 2034, 10.93% growth in Pre-Implanted Model against 8.41% in Pathological Model pulls the type mix apart. Over the forecast period that moves Pre-Implanted Model from 37% of revenue to 42%, and Pathological Model from 63% to 58%. Revenue rises on both sides; USD 155.4 million to USD 395.64 million and USD 264.6 million to USD 546.36 million respectively, so this is a change in composition, not a contraction, and one forecast window is long enough for it to matter.

Regional weight shifts toward Asia Pacific, Latin America and Middle East and Africa. Asia Pacific moves from 22% of revenue in 2025 to 28% in 2034, worth USD 92.4 million rising to USD 263.76 million; Latin America moves from 5% of revenue in 2025 to 5.5% in 2034, worth USD 21 million rising to USD 51.81 million; Middle East and Africa moves from 4% of revenue in 2025 to 4.5% in 2034, worth USD 16.8 million rising to USD 42.39 million. Against that, North America at 42% moving to 37%, Europe at 27% moving to 25%, a fall in share, not in revenue. Growth is therefore not something a participant inherits from the market; it depends on which regions its revenue is weighted toward.

Growth compounds at 9.4% without a step change. Year by year the total runs USD 265 million in 2020, USD 378 million in 2024, USD 420 million in 2025, USD 459 million in 2026, USD 657 million in 2030 and USD 942 million in 2034. No year breaks the trajectory, and the 9.4% forecast rate compares with 9.64% recorded over 2020-2025, a continuation rather than an inflection. A plan built on this market is therefore a plan about capturing a share of steady expansion, which is decided on the type and regional axes, not by the headline rate.

Growth is concentrated in Pre-Implanted Model

The 9.4% forecast rate rests on three things that can be measured separately: the size of the existing base, the mix shift on the type axis, and where regional growth is concentrated.

What holds the forecast back

Upside case: USD 1036.2 million by 2034

One type line carries the market

USD 176.4 million of 2025 revenue is generated in North America, 42% of the global rodent surgery services market and reaches USD 348.54 million by 2034. By revenue it sits first across the study, and the ranking does not change between 2025 and 2034.

Its share moves to 37% by 2034, though revenue still rises throughout; what changes is the region's weight against faster-growing ones, which is not the same as weakening demand.

Segment composition follows the global pattern: Pathological Model largest at 63% of 2025 revenue, Pre-Implanted Model fastest at 10.93%. Per-axis and per-country detail for North America sits in the full report.

85% of North America's base-year revenue comes from the United States; USD 149.94 million, rising to USD 292.7736 million by 2034. At 85% of regional revenue in the base year it is not one market among several, the region's trajectory is largely this country's trajectory. Set against USD 176.4 million and USD 348.54 million for the region, it is why this market rather than a smaller one is the one reported in full.

the United States buys along the same lines as the market globally; Pathological Model first at 63% of 2025 revenue and 58% in 2034, Pre-Implanted Model fastest at 10.93% on a share moving from 37% to 42%. Since 85% of North America's revenue is generated here, the regional numbers inherit this market's mix rather than smoothing it out. Per-type revenue for the United States appears on its own in the full report.

Surgical procedures performed on rodents for research purposes in the United States fall under the oversight of Institutional Animal Care and Use Committees, operating within the framework of the Public Health Service Policy on Humane Care and Use of Laboratory Animals administered by the Office of Laboratory Animal Welfare. Facilities conducting such procedures must maintain protocols reviewed and approved before any surgery proceeds, covering anesthesia, analgesia, and post-operative care. Providers supporting regulated preclinical studies are also expected to operate under Good Laboratory Practice standards where results support submissions to the Food and Drug Administration. Voluntary accreditation through AAALAC International is widely treated as a marker of program quality, though it is not a mandatory precondition for operating a rodent surgery service.

In the United States the field is Charles River Laboratories, Taconic Biosciences, Hilltop Lab Animals, Envigo, The Jackson Laboratory, Crown Bioscience, Janvier Labs, Cyagen Biosciences, Champions Oncology, Explora BioLabs, Altasciences, GemPharmatech, Biocytogen and Others. The commercially relevant division is 63% of 2025 revenue in Pathological Model, where the volume is, against 10.93% growth in Pre-Implanted Model, where share moves. The full report covers country-level positioning and shares company by company; this summary does not.

4.62% of global revenue is generated in Canada; USD 19.404 million in 2025, reaching USD 38.3394 million in 2034, and 11% of North America.

In Europe, 27% of global revenue puts 2025 at USD 113.4 million on the way to USD 235.5 million by 2034. It is a leading region on this axis, second by revenue throughout the period.

Share settles at 25% in 2034, though revenue still rises throughout; what changes is the region's weight against faster-growing ones, which is not the same as weakening demand.

The type mix reported at global level applies here, with Pathological Model the largest line at 63% of 2025 revenue and Pre-Implanted Model the fastest-growing at 10.93%. Per-axis and per-country detail for Europe sits in the full report.

34% of Europe's base-year revenue comes from Germany; USD 38.556 million, rising to USD 77.715 million by 2034. At 34% of the region in 2025 it leads, but a majority of Europe's revenue is generated in other markets. The region itself runs USD 113.4 million to USD 235.5 million over the same period, and this is the market carrying the country-level detail in the full report.

Demand in Germany follows the type mix reported at global level: Pathological Model is the largest line at 63% of 2025 revenue, moving to 58% by 2034, while Pre-Implanted Model grows fastest at 10.93% and takes its share from 37% to 42%. Since 34% of Europe's revenue is generated here, the regional numbers inherit this market's mix rather than smoothing it out. The full report reports Germany by type separately.

In Germany, rodent surgery performed for scientific purposes is governed by the Tierschutzgesetz, the national animal welfare law, together with its implementing ordinance on the protection of animals used for experimental and other scientific purposes, which transposes the European Union's directive on the protection of animals used for scientific purposes. Any facility or project involving surgical intervention on rodents must obtain prior authorization from the relevant regional authority, supported by an ethical justification following the principles of replacement, reduction, and refinement. Personnel performing procedures must hold documented competence recognized under the same framework, and institutions typically maintain an internal animal welfare body responsible for ongoing oversight of approved protocols.

The suppliers tracked in this study (Charles River Laboratories, Taconic Biosciences, Hilltop Lab Animals, Envigo, The Jackson Laboratory, Crown Bioscience, Janvier Labs, Cyagen Biosciences, Champions Oncology, Explora BioLabs, Altasciences, GemPharmatech, Biocytogen and Others) compete in Germany across the type lines above. Pathological Model, at 63% of 2025 revenue, is where the volume sits, and Pre-Implanted Model, growing at 10.93%, is where position changes hands over the forecast period.

7.56% of global revenue is generated in the United Kingdom; USD 31.752 million in 2025, reaching USD 68.295 million in 2034, and 28% of Europe.

Asia Pacific holds 22% of the global rodent surgery services market in 2025, worth USD 92.4 million on the way to USD 263.76 million by 2034. By revenue it sits third across the study, and the ranking does not change between 2025 and 2034.

28% of global revenue sits here by 2034, up from the 2025 level, because it outgrows the market's 9.4%; the revenue added here is disproportionate to where the region started.

Pathological Model leads here as it does globally, at 63% of 2025 revenue, and Pre-Implanted Model again grows fastest at 10.93%. Asia Pacific is reported axis by axis and country by country in the full study.

40% of Asia Pacific's base-year revenue comes from China; USD 36.96 million, rising to USD 110.7792 million by 2034. 40% of the region in the base year makes it the largest market here without making it the region. Set against USD 92.4 million and USD 263.76 million for the region, it is why this market rather than a smaller one is the one reported in full.

Demand in China follows the type mix reported at global level: Pathological Model is the largest line at 63% of 2025 revenue, moving to 58% by 2034, while Pre-Implanted Model grows fastest at 10.93% and takes its share from 37% to 42%. Its 40% weight in Asia Pacific means those movements carry straight into the regional totals. Per-type revenue for China appears on its own in the full report.

Rodent surgery conducted for research purposes in China is regulated primarily through the Regulations on the Administration of Laboratory Animals issued at the national level, supplemented by implementing rules from provincial and municipal science and technology administrations. Facilities offering such services are generally required to hold a laboratory animal usage license issued by the local science and technology bureau, covering housing conditions, personnel qualification, and procedural oversight. Where surgical work supports studies intended for regulatory submission, adherence to Good Laboratory Practice requirements set by the National Medical Products Administration also applies. Institutional ethical review of animal use protocols is expected before procedures are undertaken, reflecting the broader national push toward standardized laboratory animal governance.

Competition in China runs between the suppliers this study tracks: Charles River Laboratories, Taconic Biosciences, Hilltop Lab Animals, Envigo, The Jackson Laboratory, Crown Bioscience, Janvier Labs, Cyagen Biosciences, Champions Oncology, Explora BioLabs, Altasciences, GemPharmatech, Biocytogen and Others. Volume sits in Pathological Model at 63% of 2025 revenue; movement sits in Pre-Implanted Model at 10.93% growth.

Within Asia Pacific, Japan accounts for 27% of regional revenue and 5.94% of the global total, worth USD 24.948 million in 2025 and USD 63.3024 million by 2034.

3.3% of global revenue is generated in India; USD 13.86 million in 2025, reaching USD 50.1144 million in 2034, and 15% of Asia Pacific.

Latin America holds 5% of the global rodent surgery services market in 2025, worth USD 21 million and reaches USD 51.81 million by 2034. Among the five regions it ranks fourth by revenue in both years.

5.5% of global revenue sits here by 2034, up from the 2025 level, because it outgrows the market's 9.4%; the revenue added here is disproportionate to where the region started.

The type mix reported at global level applies here, with Pathological Model the largest line at 63% of 2025 revenue and Pre-Implanted Model the fastest-growing at 10.93%. Revenue for Latin America is broken out by every segmentation axis and by country in the full report.

The largest single market in Latin America is Brazil, at USD 10.5 million in 2025 and USD 24.8688 million in 2034. At 50% of the region in 2025 it leads, but a majority of Latin America's revenue is generated in other markets. The region itself runs USD 21 million to USD 51.81 million over the same period, and this is the market carrying the country-level detail in the full report.

Brazil buys along the same lines as the market globally; Pathological Model first at 63% of 2025 revenue and 58% in 2034, Pre-Implanted Model fastest at 10.93% on a share moving from 37% to 42%. With 50% of Latin America concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Brazil carries its own type breakdown in the full report.

In Brazil, rodent surgery performed within research settings is governed by the Arouca Law, which established the National Council for Control of Animal Experimentation as the body overseeing the ethical use of animals in teaching and research. Institutions and service providers must register with the council and route every surgical protocol through an accredited Ethics Committee on Animal Use prior to any procedure taking place. Compliance extends to facility conditions, personnel training, and documented adherence to accepted guidelines for anesthesia and post-surgical care. Providers operating without this institutional-level ethical clearance are not considered compliant, regardless of the technical standard of the surgery itself.

Charles River Laboratories, Taconic Biosciences, Hilltop Lab Animals, Envigo, The Jackson Laboratory, Crown Bioscience, Janvier Labs, Cyagen Biosciences, Champions Oncology, Explora BioLabs, Altasciences, GemPharmatech, Biocytogen and Others are the suppliers covered in Brazil. The commercially relevant division is 63% of 2025 revenue in Pathological Model, where the volume is, against 10.93% growth in Pre-Implanted Model, where share moves.

Mexico is sized at USD 6.72 million in 2025, rising to USD 17.0973 million by 2034; 1.6% of global revenue and 32% of Latin America. It is reported separately from Brazil across every segmentation axis in the full report.

In Middle East and Africa, 4% of global revenue puts 2025 at USD 16.8 million with USD 42.39 million projected for 2034. That makes it the fifth-largest region covered, in 2025 and again in 2034.

By 2034 the share has moved up to 4.5%, on growth above the market's own 9.4%, and with a bigger contribution to the revenue added over the period than the base-year figure suggests.

Within the region the type split tracks the global one; 63% of 2025 revenue in Pathological Model, fastest growth of 10.93% in Pre-Implanted Model. The full report breaks Middle East and Africa out along every axis and by country.

45% of Middle East and Africa's base-year revenue comes from Israel; USD 7.56 million, rising to USD 18.6516 million by 2034. 45% of the region in the base year makes it the largest market here without making it the region. Set against USD 16.8 million and USD 42.39 million for the region, it is why this market rather than a smaller one is the one reported in full.

Composition here matches the global split: the largest line is Pathological Model at 63% of 2025 revenue, easing to 58% by 2034, and the fastest is Pre-Implanted Model at 10.93%, from 37% to 42%. Its 45% weight in Middle East and Africa means those movements carry straight into the regional totals. Revenue by type for Israel is reported separately in the full report.

Rodent surgery carried out for research purposes in Israel falls under the Animal Welfare Law concerning experiments on animals, administered with oversight from the Ministry of Health alongside the National Council for Animal Experimentation. Any institution conducting such procedures must hold a formal license to operate an experimental facility and route each protocol through an accredited institutional ethics committee before work begins. Researchers and technicians performing surgery are expected to hold documented training recognized under the same framework, and facilities are subject to periodic inspection to confirm ongoing conformity with housing, anesthesia, and welfare requirements. This regulatory route applies irrespective of whether the work is conducted for academic or contracted commercial purposes.

Charles River Laboratories, Taconic Biosciences, Hilltop Lab Animals, Envigo, The Jackson Laboratory, Crown Bioscience, Janvier Labs, Cyagen Biosciences, Champions Oncology, Explora BioLabs, Altasciences, GemPharmatech, Biocytogen and Others are the suppliers covered in Israel. The commercially relevant division is 63% of 2025 revenue in Pathological Model, where the volume is, against 10.93% growth in Pre-Implanted Model, where share moves.

South Africa is sized at USD 4.2 million in 2025, rising to USD 11.0214 million by 2034; 1% of global revenue and 25% of Middle East and Africa. It is reported separately from Israel across every segmentation axis in the full report.

Request this sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by Type, Application, Animal Type, Indication, Service Model, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.